December 8, 2025BloodOpen Access

Oral azacitidine maintenance improved survival for t-AML or AML-MR patients in first remission after CPX-351 and not eligible to HSCT

View Full Paper

Ask AI

Bookmark

Authors

GUGeoffrey L. UySaint Louis University LCLénaïg Le ClechCentre Hospitalier de Cornouaille PLPatrick Varun LawrenceInstitute of Cancer Research

Discussion

Member takes

Implication

Retrospective analysis finds that oral azacitidine maintenance is associated with improved overall survival in t-AML and AML-MR patients after CPX-351, highlighting minimal residual disease as a progn

Key Points

Overall survival improved with oral azacitidine maintenance in patients with t-AML or AML-MR after CPX-351.
Median overall survival from oral azacitidine was 28.2 months, significantly higher than historical figures.
Observational analysis across 11 centers treated AML patients with oral azacitidine after CPX-351.
Findings suggest minimal residual disease status may be a key prognostic indicator for survival.

Cite This Study

Uy et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da89 https://doi.org/10.1182/blood-2025-3441

View Full Paper

Ask AI

Bookmark

Oral azacitidine maintenance improved survival for t-AML or AML-MR patients in first remission after CPX-351 and not eligible to HSCT

Discussion

Member takes

Implication

Key Points

Cite This Study

Oral azacitidine maintenance improved survival for t-AML or AML-MR patients in first remission after CPX-351 and not eligible to HSCT

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider